Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:21:53.023Z.
Calculation as of: 2026-10-06T16:21:53.023Z.
Quote observation: 2026-10-06T16:20:44.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d0cade57d6bc8828dc71ac364ddc44a4328d7c948fb2699a56d4eea8e3f6e5b7
PE RATIO
N/A
Market Cap
$1.35B
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alpha Tau Medical Ltd (DRTS) | $1.32B | N/A | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.35B | N/A | N/A | N/A | N/A |
| Omeros Corporation (OMER)vs › | $1.36B | 10.89 | 10.02 | 9.28 | 5.37 |
| Kardigan, Inc. (KARD)vs › | $1.27B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A | 0.13 | 0.13 | 0.13 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | N/A | N/A | N/A | N/A |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.23B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 45.33 | 39.73 | 39.80 | 78.59 |
| Omada Health (OMDA)vs › | $1.22B | 327.03 | 351.15 | 351.15 | 351.15 |
| Cronos Group Inc. (CRON)vs › | $1.22B | 18.03 | 29.62 | 28.16 | 28.16 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$14.65
Forward EPS (Est.)
$-0.96
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
